Testing effectiveness (Phase 2)WithdrawnNCT02402725What this trial is testingStudy of Ultra-High Dose Dexamethasone for Relapsed Multiple MyelomaWho this might be right forMultiple Myeloma Boston Medical Center
Testing effectiveness (Phase 2)Study completedNCT00133991What this trial is testingCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaWho this might be right forLeukemiaLymphoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Testing effectiveness (Phase 2)Ended earlyNCT00615589What this trial is testingStem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning RegimenWho this might be right forMultiple MyelomaPlasma Cell Leukemia University of Michigan Rogel Cancer Center 22
Testing effectiveness (Phase 2)WithdrawnNCT00101140What this trial is testingDonor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionWho this might be right forAdult Acute Erythroid LeukemiaAdult Acute Monoblastic and Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)Looking for participantsNCT05884333What this trial is testingCord Blood Transplant in Adults With Blood CancersWho this might be right forAcute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Chronic Myelogenous Leukemia (CML)+3 more Memorial Sloan Kettering Cancer Center 54
Testing effectiveness (Phase 2)Study completedNCT02196857What this trial is testingSorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationWho this might be right forLeukemia M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT04996875What this trial is testing(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisWho this might be right forAdvanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more Cogent Biosciences, Inc. 140
Large-scale testing (Phase 3)Ended earlyNCT00513747What this trial is testingEarly or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaWho this might be right forLeukemia Alliance for Clinical Trials in Oncology 84
Not applicableLooking for participantsNCT07183878What this trial is testingVenetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)Who this might be right forAcute Myeloid LeukemiaHigh-Risk Acute Myeloid LeukemiaMyelodysplastic Syndromes+1 more First Affiliated Hospital of Zhejiang University 138
Early research (Phase 1)WithdrawnNCT01751243What this trial is testingTransplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological MalignanciesWho this might be right forTransplant-Related Hematologic Malignancy Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Testing effectiveness (Phase 2)Looking for participantsNCT03214562What this trial is testingVenetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia M.D. Anderson Cancer Center 116
Large-scale testing (Phase 3)Study completedNCT00002576What this trial is testingCombination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's LymphomaWho this might be right forLymphoma Cancer Research Campaign Clinical Trials Centre 200
Testing effectiveness (Phase 2)UnknownNCT00838240What this trial is testingClofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk MyelodysplasiaWho this might be right forLeukemiaMyelodysplastic Syndromes European Organisation for Research and Treatment of Cancer - EORTC 114
Testing effectiveness (Phase 2)Study completedNCT00143559What this trial is testingStem Cell Transplantation as Immunotherapy for Hematologic MalignanciesWho this might be right forLeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more St. Jude Children's Research Hospital 17
Early research (Phase 1)Ended earlyNCT04477291What this trial is testingCG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSWho this might be right forAcute Myeloid LeukemiaMyelodysplastic Syndromes Aptose Biosciences Inc. 45
Early research (Phase 1)Looking for participantsNCT03326310What this trial is testingSelumetinib and Azacitidine in High Risk Chronic Blood CancersWho this might be right forChronic Myeloid LeukemiaMyelofibroses University of Chicago 18
Large-scale testing (Phase 3)Study completedNCT00454480What this trial is testingCombination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesWho this might be right forLeukemiaMyelodysplastic Syndromes The University of New South Wales 2,000
Testing effectiveness (Phase 2)Study completedNCT01341301What this trial is testingDonor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesWho this might be right forHematologic Malignancy Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 25
Early research (Phase 1)Ended earlyNCT05569512What this trial is testingUproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AMLWho this might be right forAcute Myeloid LeukemiaPediatric Cancer Malika Kapadia 1
Not applicableLooking for participantsNCT06814405What this trial is testingSafety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in HospitalWho this might be right forHaematological Malignancy IRCCS Azienda Ospedaliero-Universitaria di Bologna 100